AtheroGenics says it has launched a Phase III trial of its heart disease drug candidate, AGI-1067.

The drug is intended to reduce inflammation in blood vessel walls.

“By entering the final steps of drug development, we are bringing this promising compound another step closer to the millions of patients who are suffering from coronary heart disease,” said Dr. Rob Scott, the company’s chief medical officer and senior vice president of clinical development.